Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Middleton, MR; Hamid, O; Shoushtari, AN; Meier, FE; Bauer, TM; Salama, AKS; Kirkwood, JM; Ascierto, PA; Lorigan, P; Mauch, C; Orloff, MM; Evans, TRJ; Abdullah, SE; Yuan, Y; Mitchell, J; Hassel, JC

Published Date

  • 2022

Published In

Volume / Issue

  • 40 / 16

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X